Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
about
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapyCiprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistancePredictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.Prevention of bacterial infection in pediatric oncology: what do we know, what can we learn?Randomized double blind trial of ciprofloxacin prophylaxis during induction treatment in childhood acute lymphoblastic leukemia in the WK-ALL protocol in Indonesia.Ambulatory consolidation chemotherapy for acute myeloid leukemia with antibacterial prophylaxis is associated with frequent bacteremia and the emergence of fluoroquinolone resistant E. Coli.Once-daily, oral levofloxacin monotherapy for low-risk neutropenic fever in cancer patients: a pilot study in China.Febrile neutropenia--seven frequently asked questions and answers.The revolution of myelodysplastic syndromes.Current trends of infectious complications following hematopoietic stem cell transplantation in a single center.Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis.Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusionsA Risk Assessment of Antibiotic Pan-Drug-Resistance in the UK: Bayesian Analysis of an Expert Elicitation StudyThe strategy of antibiotic use in critically ill neutropenic patientsAntimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and OncolAntimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.The prevention and management of infections due to multidrug resistant organisms in haematology patientsEscherichia coli: an important pathogen in patients with hematologic malignancies.Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.Impact of a change in antibacterial prophylaxis on bacteremia and hospitalization rates following outpatient autologous peripheral blood stem cell transplantation for multiple myeloma.The role of prophylactic antimicrobials during autologous stem cell transplantation: a single-center experience.Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: Causes and consequences.The role of prophylaxis of bacterial infections in children with acute leukemia/non-hodgkin lymphoma.Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens.Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis.Hematological: Low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single-center study.Relapsing bloodstream infections during treatment of acute leukemia.Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms-Where Are We Today?A comparison of levofloxacin and oral third-generation cephalosporins as antibacterial prophylaxis in acute leukaemia patients during chemotherapy-induced neutropenia.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.
P2860
Q24203869-65D608C6-D924-43A6-B3F7-8723EF5E8532Q31125417-B3C0583F-742C-40D2-9ECB-B8CD58F31DFFQ33390157-18DC2581-87AB-4480-8F53-92BCF4AD6CBCQ33559453-B9F8A6E3-E7E4-46D2-AC7E-73924958506EQ34583481-44278342-87B9-410B-BA18-421FDE9303F7Q34783463-2AF0DBDF-588E-41BB-B67C-451DF06B2169Q35038916-B15AE1F1-D43B-43B5-8E6D-4BFF612E97E0Q36270114-D08E9411-D124-417E-B992-6D0C6B51E201Q36612553-DCAE7E79-CC0A-4293-94DC-B83EB4A71F9FQ37323880-2AD83BE2-6174-4C17-B038-CB9894154197Q37504803-A3F64836-1003-4C1B-A46E-00856FF43CAAQ37697210-033FAE0F-356D-4F89-932A-F75142505C20Q37729926-19CED1E5-7DC4-4917-AEE7-4E3FA7599848Q37929895-41DE431B-0453-47FE-866F-8E9E750D475BQ38013661-EE5BA6E1-C55E-4087-92F7-639797153D10Q38081793-8C018CDC-BCA4-4FE8-BF6E-4E228B298A7BQ38117578-E4EFC9A2-C3BF-4DE0-8484-8FFC0DAD824FQ38171538-9FC108F6-3A6C-4901-960D-8BBDB78AA956Q38269510-D1E0484E-0222-4C78-B0C8-BD61991FA42CQ38749061-323CB015-D366-4E53-B686-4F4CDDCC77ACQ40208242-9AA5EEFD-F372-4446-9764-682F193E8BD4Q40303842-42D7A0C9-E751-4A0D-ABB4-EF4E1BE67812Q40426291-6C4D61DE-1CE4-4DA7-8C22-F53FBBD3F3FDQ41548221-CC30C46C-F0FE-46EC-A1DF-F8C4C69CDB07Q41742650-40F75DD6-EC8A-4FFA-962F-F3C82B95D150Q43723863-37BCC5AD-F5BF-4EE8-9C0D-B0FEC4F7767DQ43984868-A2E79B64-0657-4F77-BED6-8CB0632C7706Q45355151-25B88B82-2C93-4B9F-9287-30D55D3AD904Q47709323-ECC668EE-B8A3-42E0-810C-FE3986A19E9AQ50080905-FC269C82-39B7-4DCD-ACE7-0F40C634CC51Q51617424-FC888ED6-6043-45DB-A4CA-83418A8F8F9F
P2860
Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Impact of fluoroquinolone prop ...... and hematologic malignancies.
@en
type
label
Impact of fluoroquinolone prop ...... and hematologic malignancies.
@en
prefLabel
Impact of fluoroquinolone prop ...... and hematologic malignancies.
@en
P2093
P356
P1476
Impact of fluoroquinolone prop ...... and hematologic malignancies.
@en
P2093
Anja Sigge
Heike von Baum
Peter Kern
Reinhard Marre
Stefan Reuter
Winfried V Kern
P304
P356
10.1086/428732
P407
P577
2005-03-11T00:00:00Z